← Back to Clinical Trials
Recruiting NCT07358832

NCT07358832 Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07358832
Status Recruiting
Phase
Sponsor Istituto Auxologico Italiano
Condition Homonymous Hemianopsia
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2026-02-01
Primary Completion 2028-02-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
tDCSAudio-visual training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2026-02-01 with a primary completion date of 2028-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Homonymous visual field defects (HVFDs) after acquired brain injuries affect daily life by impairing reading, navigation, and social activities, often impacting anxiety and depression. Spontaneous recovery is rare. Rehabilitation approaches include restorative treatments, which aim to expand the visual field through the stimulation of the so-called transition zone, and compensatory strategies, such as audio-visual training (AVT), which combines eye movement exercises with synchronized visual and auditory cues to train oculomotor scanning and overcome the visual field loss. Combining AVT with non-invasive brain stimulation, such as transcranial direct current stimulation (tDCS), may enhance recovery by promoting brain plasticity. Early evidence suggests that tDCS applied to the lesioned visual cortex during AVT can speed and stabilize improvements, potentially also restoring parts of the visual field. However, most studies on AVT have focused on chronic patients, whereas several clinical trials and international guidelines indicate that early treatment of HVFDs in the subacute phase can optimally exploit the window of maximal neural plasticity and prevent secondary degenerative processes, thereby maximizing visual recovery. In the present randomized clinical trial, we assess the efficacy of a multisensory audio-visual training (AVT) combined with tDCS in patients with subacute HVFDs after stroke (\<3 months post-lesion). Participants are randomly assigned to two groups: AVT combined with real anodal tDCS applied to the lesioned occipital cortex (Group 1), or AVT combined with sham tDCS (Group 2). The AVT requires participants to orient their gaze toward spatio-temporally congruent, cross-modal audio-visual stimuli (starting from a central fixation) and press a button as quickly as possible upon detecting the visual target. All stimuli are presented on 2mx2m panel embedded with 40 LEDs and loudspeakers (Diana, Casati, Melzi, Marzoli, et al., 2024). The training will be administered for 90 minutes daily over 10 consecutive days. All participants underwent a neuro-ophthalmological evaluation and neuropsychological assessment of visuospatial functions before the beginning of the training (t0), at the end of the training (t1), at 2 months (t2) and after 1 year (t3).

Eligibility Criteria

Inclusion Criteria: \- Presence of subacute acquired brain injury (\< 3 months) with HVFD according to Neurophthalmological evaluation Exclusion Criteria: * Presence of hemispatial neglect (indexed by pathological asymmetries on paper-and-pencil tests) * Disorders of conjugated eye movements * Other neurological disorders (e.g., dementia) * Exclusion criteria for brain stimulation (i.e., epilepsy or family history of epilepsy; implanted electrodes, stimulators, pacemakers, infusion pumps, or any implanted metal device; pregnancy)

Contact & Investigator

Central Contact

Nadia Bolognini, PhD

✉ n.bolognini@auxologico.it

📞 02619116127

Frequently Asked Questions

Who can join the NCT07358832 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Homonymous Hemianopsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07358832 currently recruiting?

Yes, NCT07358832 is actively recruiting participants. Contact the research team at n.bolognini@auxologico.it for enrollment information.

Where is the NCT07358832 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT07358832 clinical trial?

NCT07358832 is sponsored by Istituto Auxologico Italiano. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology